ArticleGene therapy2001
Muscle-specific enhancement of gene expression by incorporation of SV40 enhancer in the expression plasmid.
Article in Gene therapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Review
- Modifying non-coding regions of linear DNA vaccines to explore the interplay of expression and inflammation in immunogenicity.Human vaccines & immunotherapeutics · 2025Article
- COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign.Cureus · 2024Review
- Exploring the Fate of Antibody-Encoding pDNA after Intramuscular Electroporation in Mice.Pharmaceutics · 2023Article
- A Tet-Inducible CRISPR Platform for High-Fidelity Editing of Human Pluripotent Stem Cells.Genes · 2022Article
- In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies.Pharmaceutics · 2021Review
- Nucleic acid delivery to mesenchymal stem cells: a review of nonviral methods and applications.Journal of biological engineering · 2019Review
- Cytoplasmic transport and nuclear import of plasmid DNA.Bioscience reports · 2017Review
- Non-viral therapeutic approaches to ocular diseases: An overview and future directions.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- Enhanced Immune Response to DNA Vaccine Encoding Bacillus anthracis PA-D4 Protects Mice against Anthrax Spore Challenge.PloS one · 2015Article
- Novel therapeutic approaches for various cancer types using a modified sleeping beauty-based gene delivery system.PloS one · 2014Article
- Article
- Applying horizontal gene transfer phenomena to enhance non-viral gene therapy.Journal of controlled release : official journal of the Controlled Release Society · 2013Review
- Cell-specific targeting strategies for electroporation-mediated gene delivery in cells and animals.The Journal of membrane biology · 2013Review
- Simian virus 40 enhancer does not affect the tumor specificity of human heparanase gene promoter.Biomedical reports · 2013Article
- Exploring the mechanism of plasmid DNA nuclear internalization with polymer-based vehicles.Molecular pharmaceutics · 2012Article
- An artificial PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- DNA nuclear targeting sequences for non-viral gene delivery.Pharmaceutical research · 2011Article
- Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers.Gene therapy · 2011Article
- Metabolically stabilized long-circulating PEGylated polyacridine peptide polyplexes mediate hydrodynamically stimulated gene expression in liver.Gene therapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skeletal muscle is established as an ideal tissue for gene delivery to treat systemic diseases. However, the relatively low levels of gene expression obtained from using naturally occurring promoters, including the strong cytomegalovirus (CMV) enhancer/promoter (E/P), have limited the use of muscle as a target tissue. The relatively weak simian virus 40 (SV40) enhancer is known to have dual functions promoting localization of DNA to the nucleus and activating transcription. An SV40 enhancer incorporated either at the 5' end of CMV E/P or the 3' end of the polyadenylation site gave as much as a 20-fold increase in the level of exogenous gene expression in muscle in vivo, compared with expression observed with CMV E/P alone. The minimum requirement for this enhancement is a single copy of a 72-bp element of the SV40 enhancer, in combination with either the CMV E/P or skeletal actin (SkA) promoter. Enhancement of gene expression in muscle by this SV40 enhancer was also observed by using the powerful electroporation delivery. However, the SV40 enhancer does not increase the level of CMV E/P driven reporter gene expression in dividing tumor cells in vivo and in the dividing myoblast cell C2C12 in vitro. The data suggest that including this enhancer in the plasmid will enhance the level of gene production for muscle-based gene therapy.
Indexed as
Identifiers
11313829What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.